Table 1 Clinicopathological characteristics of the NSCLC patients used in this study (n/a = data unavailable)
Variable | Prognostic signature | Chemotherapy-response signature | ||
|---|---|---|---|---|
Training Series A (n = 332) | Validation Series A (n = 264) | Training Series B (n = 88) | Validation Series B (n = 109) | |
Age: Median (SD) | 65 (10) | 64 (10) | 62 (10) | 69 (9) |
Gender: Female, Male | 155 (47 %), 177 (53 %) | 141 (53 %), 123 (47 %) | 51 (58 %), 39 (42 %) | 30 (28 %), 79 (72 %) |
AJCC Stage: | I: 229 (69 %), II: 61 (18 %), III: 42 (13 %) | I: 201 (75 %), II: 63 (25 %) | I: 39 (44 %), II: 27 (31 %), III: 21 (24 %), IV: 1 (1 %) | I: 57 (52 %), II: 52 (48 %) |
Stage I: A/B | 108, 121 | 93, 97 | 5, 34 | n/a |
Stage II: A/B | 50, 11 | 13, 44 | 25, 3 | n/a |
Grade: 1/2/3/na | 48 (14 %), 163 (49 %), 117 (35 %), 4 (<1 %) | 58 (22 %), 94 (35 %), 62 (23 %), 53 (20 %) | 10 (11 %), 40 (45 %), 36 (41 %), 2 (2 %) | n/a |
Histological subtype | Adenocarcinoma: 332 (100 %) | Adenocarcinoma: 264 (100 %) | Adenocarcinoma: 88 (100 %) | Adenocarcinoma: 47 (43 %), Large cell: 10 (9 %), Squamous: 52 (48 %) |
Smoking history | Never: 33 (10 %) Former: 181 (55 %), Current: 25 (8 %), Unknown: 90 (27 %) | Never: 43 (16 %), Former/current: 170 (64 %), Unknown: 54 (20 %) | Never: 14 (16 %) Former: 65 (74 %) Current: 7 (8 %) Unknown: 2 (2 %) | n/a |
Radiotherapy | 0 | 13 (5 %) | 45 (51 %) | 0 |
Chemotherapy | 0 | 0 | 88 (100 %) | 49 (45 %) |
Original publication(s): | Sheddon et al. [10] | Sheddon et al. [10] Takeuchi et al. [11] Zhu et al. [8] Bild et al. [12] Bhattacharjee et al. [13] | Sheddon et al. [10] | Zhu et al. [8] |
Genomic platform: | Affymetrix U133A | Agilent custom array: 59 (22 %), Affymetrix U95A: 140 (53 %), U133A/Plus 2.0: 65 (25 %) | Affymetrix U133A | Affymetrix U133A |
NCBI GEO ID(s) or data source | NIH.gov1 | GSE11969, GSE14814, GSE3141, http://broad.org/MRP/lung and NIH.gov1 | NIH.gov1 | GSE14814 |
Disease specific death within 5 years | 122 (37 %) | 97 (37 %) | 47 (53 %) | 34 (31 %) |